Menu Search
Equities

Palatin Technologies Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0KF3:LSE

Palatin Technologies Inc

Actions
  • Price (USD)16.00
  • Today's Change-1.75 / -9.86%
  • Shares traded1.00
  • 1 Year change-66.32%
  • Beta0.4695
Data delayed at least 20 minutes, as of Feb 10 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.

  • Revenue in USD (TTM)8.85m
  • Net income in USD-4.81m
  • Incorporated1986
  • Employees29.00
  • Location
    Palatin Technologies Inc4-B Cedar Brook DriveCedar Brook Corporate CenterCRANBURY 08512United StatesUSA
  • Phone+1 (609) 495-2200
  • Fax+1 (609) 495-2202
  • Websitehttps://www.palatin.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.